5 Undervalued Winners Up To 6.8% And 15 Overvalued To Avoid Now

Rose’s Income Portfolio hit a 5.6% yield and reached an all-time value high for the third time in July; it’s up 12.11% YTD. The note flags 15 stocks (including MRK, GD, and AMGN) as overvalued due to proximity to 52-week highs and higher historic yields. It also lists 5 undervalued buy candidates based on price and historic yield analysis, implying a modestly constructive positioning tilt toward select names.

Analysis

Income portfolios printing new highs often reflect a scarcity premium rather than fresh fundamental acceleration. In that setup, AMGN and MRK behave more like duration assets than true growth equities: they get bid when investors are reaching for yield, but they can de-rate quickly if real rates stabilize higher or if breadth rotates back into cyclicals and biotech. The key winner is not the holdings themselves so much as the crowding effect that keeps defensive healthcare expensive until the macro tone shifts.

Over the next 1-3 months, the signal is mostly about positioning, not operating fundamentals. If the next earnings/guidance cycle is merely in-line, valuation support is fragile because the market is already paying for safety; a 5-10% relative pullback is plausible if Treasury yields back up or if dividend screens lose sponsorship. Conversely, a softer rates backdrop can keep these names pinned near highs even without upside revision, so the move is more about multiple compression than an earnings miss.

Contrarian view: the screen may be calling these names expensive for the wrong reason. High-quality healthcare income names can stay persistently dear when investors prioritize balance-sheet quality and cash returns, so an outright short is lower-conviction than a trim or premium sale. The missing data is the identity and quality of the 'undervalued' replacements; without that, this is more a capital-allocation warning than a clean alpha signal.

Key Decisions for Investors

• Trim AMGN and MRK on any further strength over the next 1-2 weeks; treat them as funding sources for cheaper income names once the undervalued list is disclosed.
• For existing longs, overwrite with 1-2 month covered calls around 5% out-of-the-money to harvest premium while capping upside in a crowded yield trade.
• Set a rates trigger: if the 10Y Treasury re-prices higher for several sessions and AMGN/MRK fail to hold recent highs, reduce exposure by another 25-50% over the next month.
• If you want a relative-value expression, wait for the undervalued candidates and then pair short AMGN/MRK against the cheaper basket rather than shorting outright today.